Beijing Borui Chuanghe Pharmaceutical

Beijing Borui Chuanghe Pharmaceutical is a clinical-stage biotechnology company based in Beijing, China, and a subsidiary of BrightGene Bio-Medical Technology. The company focuses on the development of innovative therapies for metabolic diseases, with a primary emphasis on multi-target incretin mimetics. Its lead candidate, BGM0504, is a dual GLP-1 and GIP receptor agonist currently being evaluated in Phase 2 clinical trials for the treatment of obesity and type 2 diabetes. Leveraging the manufacturing and R&D capabilities of its parent company, Borui Chuanghe aims to address the growing global burden of metabolic disorders through advanced peptide drug discovery. The company represents a strategic expansion for BrightGene into the innovative drug space, moving beyond its historical strength in complex generic active pharmaceutical ingredients.